It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
A veteran in cell therapy and oncology commercialisation
All India Institute of Ayurveda hosts ministers and showcase their achievements
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
